NEW YORK (CNNMoney.com) -- Dendreon's stock price surged immediately after the open of Friday trading, following an surprise positive vote from FDA advisors the day before, which favored the experimental prostate cancer treatment Provenge.

Dendreon's stock price nearly tripled in the first few minutes of trading, to $14.90 a share.